NCT01237444 - Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. | Biotech Hunter

Enrollment

417

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

HIV Infection

Interventions

DRUG

lopinavir/ritonavir plus one nucleoside

"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"

DRUG

lopinavir /ritonavir plus two nucleosides

"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."

Trial Locations (1)

C1202ABB

Fundacion Huesped, Ciudad de Buenos Aires